Quantitative analysis of Epstein-Barr virus (EBV)-specific CD8+ T cells in patients with chronic active EBV infection

Journal of Infectious Diseases

Volumn 190, Issue 5, 2004, Pages 985-988

  Sugaya, Naomi ^a   Kimura, Hiroshi ^a   Hara, Shinya ^a   Hoshino, Yo ^a   Kojima, Seiji ^a   Morishima, Tsuneo ^c   Tsurumi, Tatsuya ^b   Kuzushima, Kiyotaka ^b  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; HLA A24 ANTIGEN;

ADULT; ARTICLE; BLOOD LEVEL; CELL ACTIVITY; CELL SELECTION; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; HUMAN; IMMUNOLOGICAL PARAMETERS; INFECTIOUS MONONUCLEOSIS; LYMPHOCYTE COUNT; PRIORITY JOURNAL; PROTEIN BINDING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; T LYMPHOCYTE; VIRUS INFECTION; VIRUS LOAD;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; CD8-POSITIVE T-LYMPHOCYTES; CHILD; CHRONIC DISEASE; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HLA-A ANTIGENS; HUMANS; INFECTIOUS MONONUCLEOSIS; LYMPHOCYTE ACTIVATION;

EID: 4344605825     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/423285     Document Type: Article

References (15)

1. Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howley PM, eds. Virology. 4th ed. Vol 2. Philadelphia: Lippincott Williams & Wilkins, 2001:2575-627.
2. Straus SE. The chronic mononucleosis syndrome. J Infect Dis 1988; 157:405-12.
3. Kimura H, Hoshino Y, Kanegane H, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 2001; 98:280-6.
4. Kimura H, Morishima T, Kanegane H, et al. Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis 2003; 187:527-33.
5. + T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med 2002; 195:893-905.
6. + T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood 2001; 98:1872-81.
7. + T cells. Blood 2003; 101: 1460-8.
8. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997; 15:405-31.
9. Hayashi N, Kimura H, Morishima T, Tanaka N, Tsurumi T, Kuzushima K. Flow cytometric analysis of cytomegalovirus-specific cell-mediated immunity in the congenital infection. J Med Virol 2003; 71:251-8.
10. Imai S, Sugiura M, Oikawa O, et al. Epstein-Barr virus (EBV)-carrying and -expressing T-cell lines established from severe chronic active EBV infection. Blood 1996; 87:1446-57.
11. Yoshioka M, Ishiguro N, Ishiko H, Ma X, Kikuta H, Kobayashi K. Heterogeneous, restricted patterns of Epstein-Barr virus (EBV) latent gene expression in patients with chronic active EBV infection. J Gen Virol 2001; 82:2385-92.
12. Fujieda M, Wakiguchi H, Hisakawa H, Kubota H, Kurashige T. Defective activity of Epstein-Barr virus (EBV) specific cytotoxic T lymphocytes in children with chronic active EBV infection and in their parents. Acta Paediatr Jpn 1993; 35:394-9.
13. Marshall NA, Vickers MA, Barker RN. Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1. J Immunol 2003; 170:6183-9.
14. Kuzushima K, Yamamoto M, Kimura H, et al. Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLA-matched sibling to a patient with severe chronic active EBV infection. Clin Exp Immunol 1996; 103:192-8.
15. Savoldo B, Huls MH, Liu Z, et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood 2002; 100:4059-66.